




Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/015002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/517,639
		Applicant	Fong et al.
		Filing Date	June 28, 2005
		Group	1614
(37 C.F.R. § 1.98(b))		IDS Filed	March 13, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication (or Issue) Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
MG	4,298,604	11-03-1981	Hammell	—	—	
	4,491,588	01-01-1985	Rosenburg et al.	—	—	
	4,569,935	02-11-1986	Rosenberg et al.	—	—	
	4,883,792	11-28-1989	Timmins et al.	—	—	
	4,942,162	07-17-1990	Rosenberg et al.	—	—	
	5,002,938	03-26-1991	Wang et al.	—	—	
	5,110,809	05-05-1992	Wang et al.	—	—	
	5,310,545	05-10-1994	Eisen	—	—	
	5,358,959	10-25-1994	Halperin et al.	—	—	
	5,407,663	04-18-1995	Eisen	—	—	
	5,432,176	07-11-1995	Walser	—	—	
	5,643,936	07-01-1997	Halperin et al.	—	—	
	5,994,341	11-30-1999	Hunter et al.	—	—	
	6,075,056	06-13-2000	Quigley, Jr. et al.	—	—	
	6,207,703	03-27-2001	Ponikau	—	—	
MG	2001/0031799	10-18-2001	Ponikau	—	—	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
MG	ES 2064288	01-16-1995	Spain (with English translation)	—	—	
MG	WO 99/20271	04-29-1999	WIPO	—	—	

EXAMINER /Michel Graffeo/	DATE CONSIDERED 05/26/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

Sheet 2 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/015002
		Serial No.	10/517,639
		Applicant	Fong et al.
		Filing Date	June 28, 2005
		Group	1614
		IDS Filed	March 13, 2006
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
MG	Baciewicz and Baciewicz, "Ketoconazole and Fluconazole Drug Interactions," <i>Arch. Intern. Med.</i> 153:1970-1976 (1993).
	Delbarre, "On the Possible Anti-Rheumatic Effects (Immuno-Effector?) of Imidazole Derivatives," <i>Biomedicine</i> 27:97-98 (1977).
	Faergemann, "Treatment of Sebopsoriasis with Itraconazole," <i>Mykosen</i> 28:612-618 (1985).
	Flannery et al., "Levamisole," <i>Lancet</i> 1:750-751 (1975).
	Fredriksson, "Treatment of Dermatomycoses with Topical Econazole Combined With a Steroid as Compared With a Conventional Oxichinoline-Steroid Combination," <i>Curr. Ther. Res.</i> 26:958-961 (1979).
	Hantschke and Reichenberger, "Doppelblinde, Randomisierte Vergleichende in Vivo Untersuchungen Zwischen den Antimykotika Clotrimazol, Tolnaftat und Naftifin"), <i>Mykosen</i> 23:657-668 (1980).
	Ludwig et al., "Steroid-Specific Effects of Ketoconazole on Corticosteroid Disposition: Unaltered Prednisolone Elimination," <i>DICP</i> 23:858-861 (1989).
	Maloley et al., "Severe Reversible Thrombocytopenia Resulting From Butoconazole Cream", <i>DICP</i> 24:143-144. 1990
	Otterness and Niblack, "Clotrimazole and Rheumatoid Arthritis," <i>Lancet</i> 1:148 (1976).
	Panayi, "Treating Rheumatoid Arthritis with Clotrimazole," <i>Nat. Med.</i> 1:977-978 (1995).
	Rosenberg et al., "Treatment of Psoriasis with Antimicrobial Agents," <i>Seminars in Dermatology</i> 4:307-311 (1985).
	Schuermans, "Levamisole in Rheumatoid Arthritis," <i>Lancet</i> 1:111 (1975).
	Smith et al., "Phospholipid Metabolism in Polymorphonuclear Leukocytes From Rheumatoid Arthritis Patients: Effects of Non-Steroidal Anti-Inflammatory Agents and Clotrimazole," <i>Int J. Immunopharmacol</i> 11:45-55 (1989).
	van der Vleuten and van der Kerkhof, "Management of Scalp Psoriasis: Guidelines for Corticosteroid Use in Combination Treatment," <i>Drugs</i> 61:1593-1598 (2001).
	Wojtulewski et al., "Clotrimazole in Rheumatoid Arthritis," <i>Ann. Rheum. Dis.</i> 39:469-472 (1980).
	Wyburn-Mason, "Clotrimazole and Rheumatoid Arthritis," <i>Lancet</i> 1:489 (1976).
	Yamashita et al., "Lack of Pharmacokinetic and Pharmacodynamic Interactions Between Ketoconazole and Prednisolone," <i>Clin. Pharmacol. Ther.</i> 49:558-570 (1991).
MG	Zürcher et al., "Impact of Ketoconazole on the Metabolism of Prednisolone," <i>Clin. Pharmacol. Ther.</i> 45:366-372

EXAMINER	/Michel Graffeo/	DATE CONSIDERED	05/26/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

Sheet 3 of 3SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

Attorney Docket No.

50164/015002

Serial No.

10/517,639

Applicant

Fong et al.

Filing Date

June 28, 2005

Group

1614

IDS Filed

March 13, 2006

(1989).

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

~~PCT International Preliminary Examination Report (PCT/US03/17586); 3 pages.~~~~PCT International Search Report (PCT/US03/17586) (1 page), and cited document U.S. Patent No. 5,944,341  
(Hunter et al.) (page 1).~~

EXAMINER

/Michel Graffeo/

DATE CONSIDERED

05/26/2006

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

Ⓢ Examiner has not considered these documents. Documents of this type require a publication date.